How to buy CSL (CSL) shares
Learn how to easily invest in CSL shares.
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
How to buy shares in CSL
- Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
- Search for CSL. Find the share by name or ticker symbol: CSL. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until CSL reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
- Check in on your investment. Congratulations, you own a part of CSL. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
CSL stock price (ASX:CSL)Use our graph to track the performance of CSL stocks over time.
CSL shares at a glance
|52-week range||$240.7363 - $317.1362|
|50-day moving average||$304.4551|
|200-day moving average||$284.676|
|Dividend yield||$2.22 (0.71%)|
|Earnings per share (TTM)||$7.206|
Compare share trading platforms
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy CSL stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
CSL price performance over time
|1 week (2021-09-17)||0.86%|
|1 month (2021-08-25)||-0.16%|
|3 months (2021-06-25)||9.43%|
|6 months (2021-03-25)||15.63%|
|1 year (2020-09-25)||5.16%|
|2 years (2019-09-25)||31.82%|
|3 years (2018-09-25)||52.27%|
|5 years (2016-09-23)||195.30%|
Is CSL under- or over-valued?
Valuing CSL stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of CSL's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
CSL's P/E ratio
CSL's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 43x. In other words, CSL shares trade at around 43x recent earnings.
That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
CSL's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.5 billion (£1.8 billion).
The EBITDA is a measure of a CSL's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$10.3 billion|
|Operating margin TTM||30.36%|
|Gross profit TTM||$5.8 billion|
|Return on assets TTM||11.59%|
|Return on equity TTM||31.86%|
|Market capitalisation||$142.2 billion|
TTM: trailing 12 months
CSL's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like CSL.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
CSL's total ESG risk score
Total ESG risk: 27.73
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and CSL's overall score of 27.73 (as at 12/31/2018) is pretty good – landing it in it in the 40th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like CSL is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
CSL's environmental score
Environmental score: 3.04/100
CSL's environmental score of 3.04 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that CSL is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
CSL's social score
Social score: 18.57/100
CSL's social score of 18.57 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that CSL is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
CSL's governance score
Governance score: 11.12/100
CSL's governance score puts it squarely in the 5th percentile of companies rated in the same sector. That could suggest that CSL is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
CSL's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. CSL scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that CSL has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||27.73|
|Total ESG percentile||39.7|
|Environmental score percentile||5|
|Social score percentile||5|
|Governance score percentile||5|
|Level of controversy||2|
CSL share dividends
Dividend payout ratio: 40.08% of net profits
Recently CSL has paid out, on average, around 40.08% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.94% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), CSL shareholders could enjoy a 0.94% return on their shares, in the form of dividend payments. In CSL's case, that would currently equate to about A$2.22 per share.
While CSL's payout ratio might seem fairly standard, it's worth remembering that CSL may be investing much of the rest of its net profits in future growth.
The latest dividend was paid out to all shareholders who bought their shares by 1 September 2021 (the "ex-dividend date").
Have CSL's shares ever split?
CSL's shares were split on a 3:1 basis on 17 October 2007. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your CSL shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for CSL shares which in turn could have impacted CSL's share price.
CSL share price volatility
Over the last 12 months, CSL's shares have ranged in value from as little as $240.7363 up to $317.1362. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while CSL's is 0.1174. This would suggest that CSL's shares are less volatile than average (for this exchange).
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Stocks similar to CSL
CSL in the news
If You Like EPS Growth Then Check Out CSL (ASX:CSL) Before It's Too Late
CSL : Positive COVID-19 Case at Broadmeadows
Urban League of Philadelphia Names CSL's Elizabeth Walker to Board of Directors
Frequently asked questions
More guides on Finder
How to invest in the Cosmos Exploration IPO
Everything we know about the Cosmos Exploration IPO, plus information on how to buy in.
What is behind the bounce in the Zip Co share price?
Shares in BNPL provider Zip Co have slipped more than 13% in the last 6 months.
Why the AGL share price has rebounded today
Shares in electricity giant AGL Energy are down 60% in the last 12 months.
How to invest in the Dundas Minerals IPO
Everything we know about the Dundas Minerals IPO, plus information on how to buy in.
How to invest in the Kalgoorlie Gold Mining IPO
Everything we know about the Kalgoorlie Gold Mining IPO, plus information on how to buy in.
The best iron ore stocks on the ASX (2021)
We look at some of the biggest and best performing iron ore stocks in Australia.
Why are the CBA and WBC share prices stumbling today?
Shares in the major banks have risen more than 50% in the last 12 months.
How to buy Evergrande shares from Australia
Steps to owning and managing China Evergrande Group shares from Australia.
How to invest in the Hamelin Gold IPO
Everything we know about the Hamelin Gold IPO, plus information on how to buy in.
How to invest in the Lykos Metals IPO
Everything we know about the Lykos Metals IPO, plus information on how to buy in.
Ask an Expert